Recombinant Fusion Proteins

"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

Descriptor ID	D011993
MeSH Number(s)	D12.776.828.300
Concept/Terms	Recombinant Fusion Proteins Recombinant Fusion Proteins Proteins, Recombinant Fusion Fusion Proteins, Recombinant Hybrid Proteins, Recombinant Hybrid Proteins, Recombinant Proteins, Recombinant Hybrid Recombinant Hybrid Proteins Chimeric Proteins, Recombinant Chimeric Proteins, Recombinant Proteins, Recombinant Chimeric Recombinant Chimeric Proteins

Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Recombinant Proteins [D12.776.828]
Recombinant Fusion Proteins [D12.776.828.300]

Below are MeSH descriptors whose meaning is related to "Recombinant Fusion Proteins".

Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".

Recombinant Fusion Proteins
CD4 Immunoadhesins
Transcription Activator-Like Effector Nucleases
Zinc Finger Nucleases

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.

Bar chart showing 231 publications over 28 distinct years, with a maximum of 19 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	6	7
1997	0	7	7
1998	1	4	5
1999	0	9	9
2000	1	9	10
2001	1	5	6
2002	0	14	14
2003	0	19	19
2004	1	15	16
2005	0	13	13
2006	2	9	11
2007	1	12	13
2008	2	10	12
2009	2	7	9
2010	1	9	10
2011	1	8	9
2012	2	12	14
2013	2	5	7
2014	5	3	8
2015	2	8	10
2016	0	2	2
2017	0	4	4
2018	3	2	5
2019	2	3	5
2020	0	1	1
2021	0	1	1
2024	1	1	2
2025	1	1	2

Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.

Ko MY, Talebi R, Yu F, Tseng VL, Coleman AL, Hosseini H. Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab. Clin Ther. 2025 Aug; 47(8):559-565.

View in: PubMed
Tailor K, van Ree J, Stowe T, Ventura B, Sisk C, Courtis J, Camp A, Elzamzami F, van Deursen J, O'Brien R, Baron J, Lui JC. Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity. Front Endocrinol (Lausanne). 2024; 15:1523931.

View in: PubMed
Mohamedali KA, Aguirre B, Lu CH, Chandla A, Kejriwal N, Liu L, Chan AM, Cheung LH, Kok S, Duarte S, Alvarez de Cienfuegos A, Casero D, Rosenblum MG, Wadehra M. GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth. J Immunother Cancer. 2024 Dec 22; 12(12).

View in: PubMed
Sefat KMSR, Kumar M, Kehl S, Kulkarni R, Leekha A, Paniagua MM, Ackart DF, Jones N, Spencer C, Podell BK, Ouellet H, Varadarajan N. An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine. 2024 09 17; 42(22):125909.

View in: PubMed
Frias JP, Bonora E, Nev?rez Ruiz L, Hsia SH, Jung H, Raha S, Cox DA, Bethel MA, Konig M. Efficacy and safety of dulaglutide 3.0?and 4.5?mg in patients aged?younger than?65 and?65?years or older: Post hoc analysis of the AWARD-11 trial. Diabetes Obes Metab. 2021 10; 23(10):2279-2288.

View in: PubMed
Hew BE, Pangburn MK, Vogel CW, Fritzinger DC. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability. Toxicon. 2020 Sep; 184:68-77.

View in: PubMed
Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, Ando K, Weng L, Ishihara S, Ponik SM, Conklin MW, Haga H, Nagasaka A, Miyata T, Matsuyama M, Kobayashi T, Fujii T, Yamada S, Yamaguchi J, Wang T, Woods SL, Worthley D, Shimamura T, Fujishiro M, Hirooka Y, Enomoto A, Takahashi M. Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis. Cancer Res. 2019 10 15; 79(20):5367-5381.

View in: PubMed
Zhang B, Han Z, Kumar S, Gupta M, Su WW. Intein-ubiquitin chimeric domain for coordinated protein coexpression. J Biotechnol. 2019 Oct 10; 304:38-43.

View in: PubMed
Dung TT, Lee UJ, Kim MH, Kim KE, Cho HM, Fermin CD, Kim DH, Kim M. PAS1-modified optical SIS sensor for highly sensitive and specific detection of toluene. Biosens Bioelectron. 2019 Sep 15; 141:111469.

View in: PubMed
Hew BE, Fritzinger DC, Pangburn MK, Vogel CW. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins. Toxicon. 2019 Sep; 167:106-116.

View in: PubMed

People

Explore

Similar Concepts

Top Journals